Status:

COMPLETED

Evaluation of Daily Disposable Toric Soft Lenses Manufactured With an Alternative Hydration Process

Lead Sponsor:

Johnson & Johnson Vision Care, Inc.

Conditions:

Astigmatism

Eligibility:

All Genders

18-39 years

Phase:

NA

Brief Summary

This is a prospective, multi-site, dispensing, randomized, controlled, double-masked, bilateral wear, 2x2 crossover study to evaluate the safety and effectiveness of the test lens.

Eligibility Criteria

Inclusion

  • Potential subjects must satisfy all of the following criteria to be enrolled in the study:
  • Read, understand, and sign the STATEMENT OF INFORMED CONSENT and receive a fully executed copy of the form.
  • Appear able and willing to adhere to the instructions set forth in this clinical protocol.
  • Be between 18 and 39 (inclusive) years of age at the time of screening.
  • By self-report, habitually wear soft contact lenses in both eyes in a daily reusable or daily disposable wear modality (i.e. not extended wear modality). Habitual wear is defined as a minimum of 6 hours of wear per day, for a minimum of 2 days per week during last 30 days.
  • Possess a wearable pair of spectacles that provide correction for distance vision.
  • In both eyes, have astigmatic refractive error suitable for correction with the toric contact lens powers available in this study:
  • Sphere powers (DS) -1.50 through -4.00 (inclusive) in 0.25 steps
  • Cylinder powers (DC) -0.75 and -1.25
  • Axes (°) 170, 180, 10, 80, 90, 100
  • Have best corrected monocular distance visual acuity of 20/30 or better in each eye.
  • Potential subjects who meet any of the following criteria will be excluded from participating in the study:
  • Be currently pregnant or lactating.
  • Be diabetic.
  • Be currently using any ocular medications or have an ocular infection of any type.
  • By self-report, have any ocular or systemic disease, allergies, infection, or use of medication that might contraindicate or interfere with contact lens wear, or otherwise compromise study endpoints, including infectious disease (e.g., hepatitis, tuberculosis), contagious immunosuppressive disease (e.g., Human Immunodeficiency Virus \[HIV\]), autoimmune disease (e.g. rheumatoid arthritis, Sjögren's syndrome), or history of serious mental illness or seizures. See section 9.1 for additional details regarding excluded systemic medications.
  • Have habitually worn rigid gas permeable (RGP) lenses, orthokeratology lenses, or hybrid lenses (e.g. SynergEyes, SoftPerm) within the past 6 months.
  • Be currently wearing monovision or multifocal contact lenses.
  • Be currently wearing lenses in an extended wear modality.
  • Have a history of strabismus or amblyopia.
  • Be an employee (e.g., Investigator, Coordinator, Technician) or immediate family member of an employee (including partner, child, parent, grandparent, grandchild or sibling of the employee or their spouse) of the clinical site.
  • Have participated in a contact lens or lens care product clinical trial within 7 days prior to study enrollment.
  • Have clinically significant (grade 3 or higher on the FDA grading scale) slit lamp findings (e.g., corneal edema, neovascularization or staining, tarsal abnormalities or bulbar injection) or other corneal or ocular disease or abnormalities that contraindicate contact lens wear or may otherwise compromise study endpoints (including entropion, ectropion, chalazia, recurrent styes, glaucoma, history of recurrent corneal erosions, aphakia, moderate or above corneal distortion, herpetic keratitis).
  • Have fluctuations in vision due to clinically significant dry eye or other ocular conditions.
  • Have had or have planned (within the study period) any ocular or intraocular surgery (e.g., radial keratotomy, Photorefractive Keratectomy \[PRK\], Laser-Assisted in Situ Keratomileusis \[LASIK\], iridotomy, retinal laser photocoagulation, etc.).

Exclusion

    Key Trial Info

    Start Date :

    April 25 2025

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    July 14 2025

    Estimated Enrollment :

    281 Patients enrolled

    Trial Details

    Trial ID

    NCT06967129

    Start Date

    April 25 2025

    End Date

    July 14 2025

    Last Update

    December 5 2025

    Active Locations (20)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 5 (20 locations)

    1

    James R. Dugue, Optometrist

    Mission Viejo, California, United States, 92691

    2

    Scripps Poway Eyecare & Optometry

    San Diego, California, United States, 92131

    3

    Stam & Associates Eye Care

    Jacksonville, Florida, United States, 32256

    4

    Pearson Research Center PA

    Longwood, Florida, United States, 32779